38
|
Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Blok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TC, Claes KB, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas A, Hansen TV, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Loizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, De Nicolo A, Gómez-García EB. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precis Oncol 2018; 2:PO.18.00091. [PMID: 31517176 PMCID: PMC6742430 DOI: 10.1200/po.18.00091] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To describe a snapshot of international genetic testing practices, specifically regarding the use of multigene panels, for hereditary breast/ovarian cancers. We conducted a survey through the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium, covering questions about 16 non-BRCA1/2 genes. METHODS Data were collected via in-person and paper/electronic surveys. ENIGMA members from around the world were invited to participate. Additional information was collected via country networks in the United Kingdom and in Italy. RESULTS Responses from 61 cancer genetics practices across 20 countries showed that 16 genes were tested by > 50% of the centers, but only six (PALB2, TP53, PTEN, CHEK2, ATM, and BRIP1) were tested regularly. US centers tested the genes most often, whereas United Kingdom and Italian centers with no direct ENIGMA affiliation at the time of the survey were the least likely to regularly test them. Most centers tested the 16 genes through multigene panels; some centers tested TP53, PTEN, and other cancer syndrome-associated genes individually. Most centers reported (likely) pathogenic variants to patients and would test family members for such variants. Gene-specific guidelines for breast and ovarian cancer risk management were limited and differed among countries, especially with regard to starting age and type of imaging and risk-reducing surgery recommendations. CONCLUSION Currently, a small number of genes beyond BRCA1/2 are routinely analyzed worldwide, and management guidelines are limited and largely based on expert opinion. To attain clinical implementation of multigene panel testing through evidence-based management practices, it is paramount that clinicians (and patients) participate in international initiatives that share panel testing data, interpret sequence variants, and collect prospective data to underpin risk estimates and evaluate the outcome of risk intervention strategies.
Collapse
Affiliation(s)
- Sarah M. Nielsen
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Diana M. Eccles
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Iris L. Romero
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Fahd Al-Mulla
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Judith Balmaña
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Michela Biancolella
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Rien Blok
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Adelaide Caligo
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Mariarosaria Calvello
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Gabriele Lorenzo Capone
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Pietro Cavalli
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - T.L. Chris Chan
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Kathleen B.M. Claes
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Laura Cortesi
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Fergus J. Couch
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Miguel de la Hoya
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Simona De Toffol
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Orland Diez
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Susan M. Domchek
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Ros Eeles
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Anna Efremidis
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Florentia Fostira
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - David Goldgar
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Andreas Hadjisavvas
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Thomas v.O. Hansen
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Akira Hirasawa
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Claude Houdayer
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Petra Kleiblova
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Sophie Krieger
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Conxi Lázaro
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Loizidou
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Siranoush Manoukian
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Arjen R. Mensenkamp
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Setareh Moghadasi
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Alvaro N. Monteiro
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Luigi Mori
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - April Morrow
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Nadia Naldi
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Henriette R. Nielsen
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Olufunmilayo I. Olopade
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Nicholas S. Pachter
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Edenir I. Palmero
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Inge S. Pedersen
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Piane
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Marianna Puzzo
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Mark Robson
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Rossing
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Christina Sini
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Angela Solano
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Jana Soukupova
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Gianluca Tedaldi
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Manuel Teixeira
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Mads Thomassen
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Maria Grazia Tibiletti
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Amanda Toland
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Therese Törngren
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Erica Vaccari
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Liliana Varesco
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Ana Vega
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Yvonne Wallis
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Barbara Wappenschmidt
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Jeffrey Weitzel
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Amanda B. Spurdle
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Arcangela De Nicolo
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| | - Encarna B. Gómez-García
- Sarah M. Nielsen, Iris L. Romero, and Olufunmilayo I. Olopade, The University of Chicago Center for Clinical Cancer Genetics, Chicago, IL; Diana M. Eccles, University of Southampton, Southampton; Ros Eeles, Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London; Yvonne Wallis, Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; Fahd Al-Mulla, Kuwait University and Genatak Center for Genomic Medicine, Safat, Kuwait; Judith Balmaña and Orland Diez, Vall d’Hebron Institute of Oncology and University Hospital of Vall d’Hebron, Barcelona; Miguel de la Hoya, Hospital Clinico San Carlos and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; Conxi Lázaro, Catalan Institute of Oncology and CIBERONC, Barcelona; Ana Vega, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Michela Biancolella, University of Rome Tor Vergata; Maria Piane, Sapienza University of Rome and Sant’Andrea Hospital, Rome; Maria Adelaide Caligo, Santa Chiara University Hospital, Pisa; Mariarosaria Calvello, IEO, European Institute of Oncology IRCCS; Siranoush Manoukian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Gabriele Lorenzo Capone, University of Florence, Florence; Pietro Cavalli, Ospedale Cremona, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona; Laura Cortesi, University of Modena and Reggio Emilia, Modena; Simona De Toffol, Toma Advanced Biomedical Assays, Busto Arsizio; Luigi Mori, University of Brescia, Brescia; Nadia Naldi, University Hospital of Parma, Parma; Marianna Puzzo, Azienda Ospedaliera di Cosenza, Cosenza; Maria Christina Sini, Institute of Biomolecular Chemistry, National Research Council, Sassari; Gianluca Tedaldi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Maria Grazia Tibiletti, Ospedale di Circolo, ASST dei Sette Laghi, Varese; Liliana Varesco, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genoa; Arcangela De Nicolo, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Rien Blok and Encarna B. Gómez-García, Maastricht University Medical Center, Maastricht; Arjen R. Mensenkamp, Radboud University Medical Center, Nijmegen; Setareh Moghadasi, Leiden University Medical Centre, Leiden, the Netherlands; T.L. Chris Chan, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Kathleen B.M. Claes, Ghent University Hospital, Ghent, Belgium; Fergus J. Couch, Mayo Clinic, Rochester, MN; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; Anna Efremidis, Athens Medical Center; Florentia Fostira, National Centre for Scientific Research Demokritos, Athens, Greece; David Goldgar, University of Utah School of Medicine, Salt Lake City, UT; Andreas Hadjisavvas and Maria Loizidou, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; Thomas v.O. Hansen and Maria Rossing, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Henriette R. Nielsen and Mads Thomassen, Odense University Hospital, Odense; Inge S. Pedersen, Aalborg University Hospital, Aalborg, Denmark; Akira Hirasawa, Keio University School of Medicine, Tokyo, Japan; Claude Houdayer, Université Paris Descartes and Unicancer Genetic Group, Paris; Sophie Krieger, Normandy University, Cancer Center F. Baclesse, and Unicancer Genetic Group, Caen, France; Petra Kleiblova and Jana Soukupova, Charles University, Prague, Czech Republic; Alvaro N. Monteiro, Moffitt Cancer Center, Tampa, FL; April Morrow, Prince of Wales Hospital and Community Health, Randwick, New South Wales; Nicholas S. Pachter, King Edward Memorial Hospital, Perth, Western Australia; Amanda B. Spurdle, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Edenir I. Palmero, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; Angela Solano, University of Buenos Aires, Buenos Aires, Argentina; Manuel Teixeira, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Amanda Toland, Ohio State University, Columbus, OH; Therese Törngren, Lund University, Lund, Sweden; Erica Vaccari, Dana-Farber Cancer Institute, Boston, MA; Barbara Wappenschmidt, University Hospital Cologne and German Consortium of Hereditary Breast and Ovarian Cancer, Cologne, Germany; and Jeffrey Weitzel, City of Hope, Duarte, CA
| |
Collapse
|